Want to see CBIO full AI Analyst Report?
CBIO Stock Chart & Stats
$16.30
$0.94(5.77%)
At close: 4:00 PM EDT
$16.30
$0.94(5.77%)
Day’s Range― - ―
52-Week Range$8.72 - $27.41
Previous CloseN/A
Volume130.39K
Average Volume (3M)145.41K
Market Cap
$625.50M
Enterprise Value$383.42
Total Cash (Recent Filing)$171.59M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 05, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding37,143,940
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.61
Price to Sales (P/S)11.39
P/FCF Ratio-0.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.50Price Target Upside80.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.94
Revenue Forecast (FY)$1.82M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative DebtExtremely low reported debt provides durable financial flexibility for a biotech with high cash needs. Low leverage reduces near-term solvency risk, supports access to financing on better terms, and gives management time to advance programs without immediate refinancing pressure.
Modest Recurring Revenue And GrowthA positive year-over-year lift in revenue, while small, indicates some commercial or partnership traction rather than zero revenue. This nascent revenue base can help partially offset R&D spend, validate market demand, and serve as a foundation to scale if pipeline assets progress.
Governance Continuity And Auditor RatificationShareholder support for directors and the auditor preserves continuity in oversight and financial reporting. Adoption of annual say-on-pay tightens governance feedback loops, which can improve alignment between management and investors over strategic and compensation decisions.
Bears Say
Heavy Operating And Free Cash BurnSustained very large negative operating and free cash flows create a structural funding imperative. Over multiple quarters this elevates refinancing, dilution, or cutbacks risk, constraining strategic optionality and potentially delaying or scaling back clinical programs.
Deep, Persistent Operating LossesVery large operating losses relative to modest revenue indicate the core model is not generating earnings and relies on external funding. Persistently negative margins weaken returns on invested capital and mean the company must either materially scale revenue or reduce fixed R&D/SG&A spend to reach sustainability.
Eroding Equity Base Increases Funding RiskA declining equity cushion reflects accumulated losses and/or financing impacts, reducing the balance-sheet buffer against shocks. Lower equity heightens reliance on fresh capital, increasing the probability of dilutive raises or onerous financing terms that can impair long-term shareholder value.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $8.72 and its highest was $27.41 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $625.50M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 87 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Jul 30, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.736 by -$0.004.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate is -0.66.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 37,143,940 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.736. Following the earnings report the stock price went up 1.693%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (80.98% Upside)
$29.50 (80.98% Upside)
Hedge Fund Trend
Decreased
By 624.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$29.50
▲(80.98% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―
Ownership Overview
11.26% Insiders
5.25% Mutual Funds
2.02% Other Institutional Investors
76.42% Public Companies and
Individual Investors










